E-resources
-
Yurkovetskiy, Aleksandr V; Bodyak, Natalya D; Yin, Mao; Thomas, Joshua D; Clardy, Susan M; Conlon, Patrick R; Stevenson, Cheri A; Uttard, Alex; Qin, LiuLiang; Gumerov, Dmitry R; Ter-Ovanesyan, Elena; Bu, Charlie; Johnson, Alex J; Gurijala, Venu R; McGillicuddy, Dennis; DeVit, Michael J; Poling, Laura L; Protopopova, Marina; Xu, Ling; Zhang, Qingxiu; Park, Peter U; Bergstrom, Donald A; Lowinger, Timothy B
Molecular cancer therapeutics, 05/2021, Volume: 20, Issue: 5Journal Article
After significant effort over the last 30 years, antibody-drug conjugates (ADC) have recently gained momentum as a therapeutic modality, and nine ADCs have been approved by the FDA to date, with additional ADCs in late stages of development. Here, we introduce dolaflexin, a novel ADC technology that overcomes key limitations of the most common ADC platforms with two key features: a higher drug-to-antibody ratio and a novel auristatin with a controlled bystander effect. The novel, cell permeable payload, auristatin F-hydroxypropylamide, undergoes metabolic conversion to the highly potent, but less cell permeable auristatin F to balance the bystander effect through drug trapping within target cells. We conducted studies in mice, rats, and cynomolgus monkeys to complement characterization and contrasted the performance of dolaflexin with regard to antitumor activity, pharmacokinetic properties, and safety in comparison with the ADC platform utilized in the approved ADC ado-trastuzumab emtansine (T-DM1). A HER2-targeted dolaflexin ADC was shown to have a much lower threshold of antigen expression for potent cell killing , was effective in tumors with low HER2 expression, and induced tumor regressions in a xenograft model that is resistant to T-DM1.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.